Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Developments on March 1, 2018
February 08, 2018 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
February 05, 2018 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 31, 2018 18:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Pre-Announces Fourth Quarter 2017 Revenue and Provides Full-Year 2018 Revenue Guidance for EXONDYS 51® (eteplirsen), Representing Approximately 100 Percent Year-over-Year Growth
January 08, 2018 13:42 ET
|
Sarepta Therapeutics, Inc.
-- Fourth quarter 2017 EXONDYS 51 unaudited revenue of $57.3 million -- -- Full-year 2017 EXONDYS 51 unaudited revenue of $154.6 million -- -- Full-year 2018 EXONDYS 51 revenue guidance of $295 –...
Sarepta Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
January 02, 2018 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 29, 2017 18:00 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 29, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Announces Publication of Long-Term Pulmonary Function of Eteplirsen-Treated Patients Compared to Natural History of Duchenne Muscular Dystrophy in The Journal of Neuromuscular Diseases
December 27, 2017 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 27, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Elects Biopharmaceutical Veteran, Michael W. Bonney, to its Board of Directors
December 05, 2017 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 30, 2017 18:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Announces Exercise of Initial Purchasers’ Option to Purchase Additional Convertible Senior Notes Due 2024
November 09, 2017 21:45 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...